Another look at compounded post-shortage

Fierce Pharma has another one of the type of articles we've been seeing a lot of — one that looks at the post–GLP-1 shortage landscape, and where compounders fit in. Its article, "After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in" includes APC's Scott Brunner as one of those experts.

He gives the explanation we've been giving for years now — explaining when drugs can be compounded, and of course pushing back against the tired industry lies about compounded products being somehow substandard. Slowly but surely, the information is getting out there, even if it's one article at a time.